European Hematology Association

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023
Diamond, Sodium- and chloride-dependent glycine transporter 1, Interim, Diamond–Blackfan anemia, Ruxolitinib, Chronic kidney disease, European Hematology Association, OrbiMed, AURORA, G&A, Porphyria, Inflammation, MF, Dialysis, Net, Congress, IRON, ATM, Erythropoiesis, Glycine, Development, Patient, Administration, Anemia, EHA, Mab, Research, FDA, Polycythemia, CKD, IND, NIH, TMPRSS6, Safety, Pharmaceutical industry, Generic drug, Vaccine, Cryptocurrency, Nursing, Disc, EPP, Greater China

Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.

Key Points: 
  • Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.
  • Announced a collaboration with NIH to study bitopertin in patients with Diamond-Blackfan Anemia in March 2023; the study is expected to initiate mid-year 2023.
  • First Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $236.4 million as of March 31, 2023 compared to $194.6 million as of December 31, 2022.
  • Net Loss: The net loss was $22.8 million for the first quarter of 2023, as compared to $9.9 million for the first quarter of 2022.

Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress

Retrieved on: 
Monday, May 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, European Hematology Association, CD16, Cancer, NK, Euronext Paris, IPH, IPHA, NCR1, EHA, Congress, Therapy, Natural killer T cell, Tetra, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany.
  • ANKET® is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
  • By providing proliferation and activation signals targeted to NK cells, tetra-specific ANKET® leverages the advantages of harnessing NK cell effector functions against cancer cells.
  • IPH6501, the first tetra-specific ANKET®, continues toward a Phase 1 clinical trial in 2023.

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

Retrieved on: 
Friday, May 12, 2023
University College London, UCL, European Hematology Association, ALL, Safety, Doctor of Philosophy, Acute leukemia, Congress, Royal College of Pathologists, EHA, Therapy, Vaccine, MD

LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 - 11, 2023, in Frankfurt.

Key Points: 
  • LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress, being held June 8 - 11, 2023, in Frankfurt.
  • Safety and efficacy of Obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19CAR in relapsed/refractory adult B-Cell acute lymphoblastic leukemia (r/r B-ALL): Topline results of the pivotal FELIX study
    Presenting Author: Dr. Claire Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Retrieved on: 
Thursday, May 11, 2023
University, European Hematology Association, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, DSM-IV codes, University of Washington, Lymphoma, Associate, Translation, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Mustang, Conference, Safety, Pharmaceutical industry

WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”), will be presented at the European Hematology Association (“EHA2023”) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma (“ICML”) taking place June 13-17, 2023, in Lugano, Switzerland.

Key Points: 
  • Both presentations will be given by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutchinson Cancer Center (“Fred Hutch”) and University of Washington.
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutch.
  • “As we continue to progress our CD20-targeted CAR T cell therapy program, we look forward to the upcoming presentations highlighting data from the Phase 1/2 study of MB-106 taking place at Fred Hutch.
  • “Looking ahead, Mustang plans to provide a data update in the near future from our Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 in a multicenter setting.”
    Details of the presentations are as follows:

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023
AACR, CD19, European Hematology Association, ADCC, Non-Hodgkin lymphoma, Lymphoma, Cyclophosphamide, G&A, NK, Antibody, Doctor of Philosophy, CAR, AML, Asilomar International Conference on Climate Intervention Technologies, Patient, Investment, The Retreat, Cytarabine, EHA, R, Research, Conference, NKG2D, Safety, D, Pharmaceutical industry, Vaccine, Cash

Cash and Cash Equivalents: As of March 31, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $332.1 million.

Key Points: 
  • Cash and Cash Equivalents: As of March 31, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $332.1 million.
  • Non-cash stock-based compensation expense included in R&D expense was $2.1 million for the first quarter of 2023.
  • Non-cash stock-based compensation expense included in G&A expense was $2.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $30.8 million, or $0.63 per basic and diluted share, for the first quarter of 2023.

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Retrieved on: 
Thursday, May 11, 2023
Control(human, data, sound), Abstract (summary), CD19, European Hematology Association, ICML, Lymphoma, NK, Mexican International Conference on Artificial Intelligence, SAN, EHA, Conference, Treatment, Vaccine

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).
  • NKX019 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target the B-cell antigen CD19.
  • Nkarta continues to plan to present an update to these data later in 2023.
  • The presentations will be made available electronically on the Nkarta website following their delivery at the scheduled scientific sessions.

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

Retrieved on: 
Thursday, May 11, 2023
Haematopoiesis, MDS, Abstract, ALK2, Therapy, Patient, European Hematology Association, KROS, EHA, Pharmaceutical industry

LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 28th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 8 through 15, 2023.

Key Points: 
  • LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 28th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 8 through 15, 2023.
  • The following abstracts were posted to the EHA website on May 11, 2023, 10:00 a.m. Eastern time.
  • “KER-050 treatment improved markers of erythropoietic activity and hematopoiesis over six months which resulted in hematological responses across a broad, lower-risk MDS population”

EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings

Retrieved on: 
Thursday, May 11, 2023
Ruxolitinib, Partnership, Peripheral T-cell lymphoma, MorphoSys, European Hematology Association, Primary myelofibrosis, Half-life, American Society of Clinical Oncology, Bone marrow, Lenalidomide, Joint Planning and Development Office, FSE, Immunotherapy, ASCO, BET, Pancreatic serous cystadenoma, Intolerance, Cancer, Patient, Lymphoma, EHA, Annual general meeting, EZH2, EZH1, Society, Disease, Pharmaceutical industry, Medical imaging, Tafasitamab, Hydroxycarbamide

“The data we are presenting at ASCO and EHA showcase the breadth and depth of our mid- to late-stage pipeline.

Key Points: 
  • “The data we are presenting at ASCO and EHA showcase the breadth and depth of our mid- to late-stage pipeline.
  • Monjuvi in combination with lenalidomide was investigated in the Phase 2 L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.
  • The presentations on Monjuvi include:
    An e-publication at ASCO and EHA of a new five-year sub-group analysis from L-MIND.
  • At ASCO, preliminary results from the Phase 2 portion of the study evaluating tulmimetostat across multiple tumor types will be presented during a poster session.

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

Retrieved on: 
Thursday, May 11, 2023
Neutropenia, GSK, Arm, SCR, European Hematology Association, Diarrhea, CD3, CRS, Immunomodulatory imide drug, Multiple myeloma, Cancer, Janssen, Nomenclature of monoclonal antibodies, KVA, ASCO, Congress, Nirogacestat, GSK plc, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Anemia, Janssen Pharmaceuticals, Annual general meeting, EHA, CR, Toxic leukoencephalopathy, RRMM, Teclistamab, FDA, Therapy, Society, ORR, BCMA, Safety, Fatigue, Pharmaceutical industry

“These data provide further validation of the mechanistic approach supporting nirogacestat’s ability to enhance the activity of BCMA-directed therapies across modalities.

Key Points: 
  • “These data provide further validation of the mechanistic approach supporting nirogacestat’s ability to enhance the activity of BCMA-directed therapies across modalities.
  • We are pleased that updated data from the GSK-sponsored trial continue to support our thesis that the combination with nirogacestat may further optimize the benefit-risk profile of belamaf monotherapy.
  • “This is the first clinical data set of nirogacestat in combination with a BCMA bispecific agent.
  • “Nirogacestat is being evaluated in combination with three other bispecific agents and we look forward to generating more data with these combinations.”

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Retrieved on: 
Thursday, May 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Abstract, Pros, European Hematology Association, Multiple myeloma, TCE, American Society of Clinical Oncology, RCT, Spectroscopy, Trial of the century, ASCO, Congress, CAR, Patient, Risk, Randomized controlled trial, Quality of life (healthcare), EHA, Annual general meeting, MM, RRMM, Society, Pharmaceutical industry, Nursing, Idecabtagene vicleucel

The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma (idecabtagene vicleucel) in patients with relapsed and/or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma.

Key Points: 
  • The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma (idecabtagene vicleucel) in patients with relapsed and/or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma.
  • “These data highlight the growing body of evidence that further support the value of Abecma across various subgroups of patients with triple-class-exposed relapsed and/or refractory multiple myeloma, who, despite recent advancements, still need more effective treatment options sooner,” said Steve Bernstein, M.D., chief medical officer, 2seventy bio.
  • Additional analysis of outcomes by number of prior lines of therapy from the KarMMa-3 clinical trial showcasing the use of Abecma in patients who received two to four prior lines of therapy.
  • Patient-reported outcomes from the pivotal Phase 3 KarMMa-3 trial in patients with triple-class exposed RRMM treated with Abecma versus standard regimens.